The direct reductive N-benzylation of imines by reaction with benzyl bromide derivatives, in the presence of [RuCl2(p-cymene)]2catalyst and PhSiH3, is performed under mild conditions without additional base. This reaction proceeds by a tandem iminehydrosilylation/nucleophilic substitution with benzyl bromide derivatives to result the tertiary amines.
Cyclopentadienyl N-heterocyclic carbene–nickel complexes as efficient pre-catalysts for the hydrosilylation of imines
作者:Linus P. Bheeter、Mickaël Henrion、Michael J. Chetcuti、Christophe Darcel、Vincent Ritleng、Jean-Baptiste Sortais
DOI:10.1039/c3cy00514c
日期:——
The in situ generated nickel hydride complex, [Ni(Mes2NHC)HCp], and its cationic analogue, [Ni(Mes2NHC)(NCMe)Cp](PF6), are efficient and chemoselective pre-catalysts for the hydrosilylation of both aldimines and ketimines under mild conditions.
Amine Synthesis through Mild Catalytic Hydrosilylation of Imines using Polymethylhydroxysiloxane and [RuCl2(arene)]2 Catalysts
作者:Bin Li、Jean-Baptiste Sortais、Christophe Darcel、Pierre H. Dixneuf
DOI:10.1002/cssc.201100585
日期:2012.2.13
Tolerate silicone! The stable [RuCl2(p‐cymene]2 complex is an efficient catalyst for the direct chemoselective hydrosilylation of functionalized aldimines and ketimines into amines, usingpolymethylhydroxysiloxane as an inexpensive, stable, and safe hydrosilane source. The catalysis operates in ethanol, under air at room temperature, and tolerates the ketone ester and alkene functionality.
NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
申请人:CHONG KUN DANG PHARMACEUTICAL CORP.
公开号:US20160083354A1
公开(公告)日:2016-03-24
The present invention relates to novel urea derivatives and, more particularly, to novel urea derivatives with histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, their use for the preparation of a medicaments comprising the same, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing novel urea derivatives. The novel urea derivatives as selective histone deacetylase (HDAC) inhibitors are effective for the treatment of histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, neurodegeneration, etc.
An electrochemical reduction of imines to amines is developed using H2O as a H-source. By tuning the reaction by using a carbon paper cathode, the undesired HER is suppressed, thereby achieving high faradaic efficiency.